MedTrace Logo

PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment

NCT04331912 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-05-13

No results posted yet for this study

Summary

This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, imaging, biochemical disease progression and no standard method of treatment hormone overproduction symptoms. The data of patients with advanced NEN with histopathological confirmation is collected from medical records. The progression-free survival (PFS), overall survival (OS) and influence of various factors on survival will be estimated. The research will be conducted for above 3 years on planned group 1500 patients. The aim of the study is to estimate median OS and PFS in advanced NEN patients treated with different schedule of systemic treatment.

Conditions

Sponsors & Collaborators

  • University of Warmia and Mazury

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
87 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04331912 on ClinicalTrials.gov